November 7, 2016

PositiveID's Caregiver Non-Contact Thermometer Exceeds Industry Laboratory Standards and Shows High Level of Agreement in Pediatric Study

Caregiver non-contact thermometer proven accurate and reliable in pediatric populations

DELRAY BEACH, Fla., Nov. 07, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its Caregiver® non-contact, infrared thermometer exceeds industry laboratory standards for accuracy and showed a high level of agreement in a pediatric study. Caregiver, which uses TouchFree™ technology, eliminates the need to take oral or rectal temperatures, thus improving ease of use and patient comfort.

In a one-year pediatric validation study, temperature measurements were obtained with an oral predictive thermometer and the Caregiver thermometer.  This validation study indicates a high level of agreement between the Caregiver and a calibrated oral predictive reference device thermometer, thus assuring accurate and reliable readings in children and adolescents age 0 to 18 years old. 

Marketed by PositiveID's Thermomedics subsidiary, Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

"Caregiver is not only easier to use than most common thermometry devices, it is proven to be just as accurate and reliable," stated William J. Caragol, Chairman and CEO of PositiveID. "We believe it also offers an improved patient experience since it is completely non-invasive, which is particularly important in pediatric populations."

Data were collected in family medicine (clinic, hospital and home care) and pediatrics (outpatient, sick baby room, and hospital ward) departments at China Medical University Hospital (Taichung, Taiwan) over a one-year period.

October 24, 2016

PositiveID's Caregiver Average Monthly Sales Increase by 60% Among Customers Participating in National Group Buy Program

Vizient, Inc.'s National Group Buy Program Generates Significant Sales Increases for Caregiver

DELRAY BEACH, Fla., Oct. 24, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today sales increased for its Caregiver® non-contact thermometer among accounts served by Vizient, Inc., the largest member-driven health care performance improvement company in the country, during its National Group Buy Program.  Average monthly sales to Vizient's customers increased approximately 60% during the second and third quarters of 2016, compared to average monthly sales to Vizient's customers during the first quarter of 2016, when no National Group Buy program was in place for Caregiver.

Marketed by PositiveID's Thermomedics subsidiary, Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

"Being a part of programs like Vizient's group buy is just one example of the types of improvements we continue to make as we focus on sales and marketing efforts for Caregiver following our acquisition of Thermomedics in December 2015," stated William J. Caragol, Chairman and CEO of PositiveID. "We believe that as we expand our distribution channel, increase our participation at tradeshows, implement trials in hospitals, advertise, etc. we will see sustained sales growth for the Caregiver product."

Vizient, Inc. is the largest member-driven health care performance improvement company in the country, and provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient's diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents almost $100 billion in annual purchasing volume. The National Group Buy program is one of several innovative programs from Vizient designed to deliver additional savings each quarter to the hospitals it serves.

September 3, 2016

PositiveID to Launch Bluetooth Version of its Caregiver Non-Contact Thermometer by Early 2017

Bluetooth-enabled Caregiver will connect wirelessly to electronic health record systems and patient monitoring stations

DELRAY BEACH, Fla., Sept. 13, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it expects to launch a Bluetooth® version of its FDA-cleared Caregiver® infrared, non-contact thermometer by early 2017.  The Bluetooth-enabled Caregiver is designed to connect wirelessly to electronic health record (EHR) systems and other hospital equipment such as patient monitoring stations.

The new Caregiver Bluetooth-enabled thermometer uses the latest low energy version Bluetooth 4.0 known as "Bluetooth Smart" for maximum battery life.  The standardized Bluetooth Health Thermometer profile is incorporated into Caregiver for maximum flexibility to automatically transmit measured temperature to a wide variety of hospital systems and telemedicine platforms.

Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

"We constantly strive to improve our offerings within all of our business lines to equip our current and potential customers with the most advanced, best-in-class products," said William J. Caragol, Chairman and CEO of PositiveID. "By maintaining a leading technological position in the temperature monitoring market with this latest Bluetooth-enabled model of Caregiver, we can help improve the standard of care for patients while simplifying the providers' role as well."

The global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc.

July 25, 2016

PositiveID's Caregiver Non-Contact Thermometer Outperforms in Evidence-Based Study

Veterans Affairs San Diego Healthcare System PACU Nurses Prefer Caregiver over Temporal Artery Thermometer Due to Ease of Use

DELRAY BEACH, Fla., July 25, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSIDD), a life sciences company focused on detection and diagnostics, announced today its FDA-cleared Caregiver® non-contact thermometer outperformed a temporal artery thermometer in every category evaluated during a Veterans Affairs San Diego Healthcare System study of Post Anesthesia Care Unit ("PACU") patients.

In the evidence-based study of 40 patients, PACU nurses evaluated the Caregiver thermometer and a temporal artery thermometer within the following categories: ease-of-use, speed, reliability, patient comfort, ease of care, and overall performance. In every category studied, the Caregiver no-touch thermometer outperformed the temporal artery thermometer.

The goals of the study, To Touch or Not to Touch? That is the Question; Using the Evidence to Change Thermometry Practice, were to determine if a temporal artery thermometer and the Caregiver non-contact thermometer compare favorably to an oral thermometer, and allow PACU nurses to determine their thermometer preference and recommend a practice change. In the study, patients had their temperature recorded using an oral electronic thermometer, a tympanic and temporal artery thermometer, and the Caregiver no-touch forehead thermometer. While the tympanic and temporal artery thermometer and Caregiver were all found to be clinically acceptable, the PACU staff unanimously agreed to move forward with the Caregiver thermometer due to ease of use.

"We routinely receive positive feedback from healthcare practitioners who use our Caregiver thermometer for its accuracy, reliability and ease of use," stated William J. Caragol, Chairman and CEO of PositiveID. "We are very pleased with the results of this evidence-based study, which, we believe not only further substantiate the value proposition of Caregiver with hard data, but also highlight the benefits of using Caregiver particularly in certain patient populations."

Caregiver, which is FDA-cleared for clinical use, utilizes infrared technology for measurement of forehead temperature in adults, children, and infants without contact. The Caregiver thermometer has documented clinical precision and is capable of high-volume use. The device meets all ASTM specifications for use in a clinical setting.

The authors of the Evidence-Based Practice Institute study were John Shurilla-Finnigan, RN, BSN, and Mary Beth Tucker, APRN, CCNS of the VA San Diego Healthcare System, San Diego, CA. This material is the result of work supported with the resources and the use of facilities at the VA San Diego Healthcare System, San Diego, CA. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

The study summary may be found at www.thermomedics.com/clinical-studies/.

February 29, 2016

PositiveID's Caregiver Non-Contact Thermometer Records an Estimated 50 Million Temperatures in 2015

DELRAY BEACH, Fla., Feb. 29, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its Caregiver® FDA-cleared, non-contact thermometer, marketed by the Company's Thermomedics subsidiary, recorded an estimated 50 million temperatures in 2015. The Caregiver thermometer is targeting the infrared temperature monitoring device market, which is the fastest growing segment of the global temperature monitoring device market estimated at $1 billion by 2020.

Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in 1-2 seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

"The increasing demand for infrared thermometers like Caregiver, which we believe is due to outstanding performance and the ability to limit the spread of infectious diseases and reduce health care costs, is driving growth in the non-contact temperature monitoring device market," stated William J. Caragol, Chairman and CEO of PositiveID. "With our recent announcement last month that we entered into new agreements with five healthcare products distributors, adding to the existing distribution channel we have established for Caregiver, we are confident we can continue to grow Caregiver's penetration in the fastest growing segment of the overall market."

The global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc. The Company's estimated number of temperatures is based on its installed base and industry estimates of the average number of beds and temperatures taken per bed in hospitals daily.

February 11, 2016

PositiveID Corporation's Thermomedics' Subsidiary Signs Deals with Five New Healthcare Products Distributors in January

DELRAY BEACH, Florida, February 11, 2016 /PRNewswire/ --PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared non-contact thermometer, made significant progress on its growth plan in January 2016, including entering into agreements with five new healthcare products distributors, increasing sequential monthly sales growth, and establishing several near-term pipeline opportunities.

Thermomedics' Caregiver thermometer is targeting the fastest growing segment of the global temperature monitoring device market, estimated at $1 billion by 2020. Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in 1-2 seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs.

It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone. Other methods of clinical thermometry, which include predictive oral/rectal/axillary electronic, infrared tympanic, temporal artery contact scanner, etc., may require expensive protective probe covers, intensive technique concentration, which make them prone to mistaken placement or dwell time, and many have the potential to need replacement metal probes, cords, or other parts.

"January 2016 was the first full month of Thermomedics operations under PositiveID's management control," stated William J. Caragol, Chairman and CEO of PositiveID. "We already see that by better capitalizing the business, entering into new distribution agreements, managing inventory, and planning for the future, we can generate immediate results in this business operationally and financially. We expect Caregiver to be an important contributor to PositiveID's 2016 total revenues, and with extremely attractive gross margins for this product we are looking to ramp Caregiver sales as quickly as possible."

Caregiver is the world's first non-contact thermometer with TouchFree™ technology and was developed by the inventors of tympanic thermometry, who continue to lead the sales effort for Caregiver. The Company markets and sells the Caregiver thermometer primarily through healthcare products distributors.

The global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc.

December 8, 2015

PositiveID Corporation Closes Transaction With Thermomedics and the Caregiver Non-Contact Thermometer

PositiveID Assumes Full Control of Thermomedics and Caregiver Immediately

DELRAY BEACH, Fla., Dec. 08, 2015 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company with an extensive patent portfolio, announced today that it has entered into a First Amendment to the Stock Purchase Agreement to acquire Thermomedics, Inc., which markets the FDA-cleared Caregiver® non-contact thermometer, and entered into a Management Services and Control Agreement, whereby the seller of Thermomedics has fully transferred control of Thermomedics to PositiveID.

In conjunction with these agreements, PositiveID has replaced all of the directors and officers of Thermomedics, Inc. Gary O'Hara, Chief Technology Officer of Thermomedics, and Ron Benincasa, Vice President of Sales and Marketing of Thermomedics, will continue as the leaders of the Caregiver business.

Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination and saves healthcare facilities the cost of covers (which are as much as $0.05 to $0.15 per temperature), storage space, and waste disposal costs. Caregiver is the world's first non-contact device with TouchFree™ technology and was developed by the inventors of tympanic thermometry.

Thermomedics currently has agreements with the world's leading healthcare product distributors. The established distribution and customer channels, including the federal government, for Caregiver are expected to provide synergies to PositiveID as it continues the development and testing of its Firefly Dx real-time pathogen detection system and prepares for commercialization.

"We are very excited about the evolving business opportunities for Caregiver, which we expect to contribute revenue to the Company in 2016," stated William J. Caragol, Chairman and CEO of PositiveID. "Further, the additional qualitative synergies of an experienced management team with proven regulatory, sales, distribution and manufacturing expertise we believe will be of great value when we reach commercialization of Firefly Dx."

The global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc.

Pursuant to the Management Services and Control Agreement, PositiveID has sole responsibility for all strategic, operational and financial decisions of Thermomedics and will be fully responsible for its financial obligations.  PositiveID will also benefit from any and all revenue generated by Thermomedics. The Company expects the closing of the Stock Purchase Agreement to occur in the first quarter of 2016.

Further details of the First Amendment to the Stock Purchase Agreement and the Management Services and Control Agreement are described in a Form 8-K filed with the SEC by PositiveID on December 7, 2015.

 

February 24, 2015

Sanomedics Signs Comprehensive Distribution Agreement
With Alliant Healthcare Products

Distribution Agreement Provides Direct Access to Federal Supply Channels

MIAMI, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Sanomedics, Inc. (OTCBB:SIMH) (OTCBB:SIMHD) ("Sanomedics" or the "Company"), a medical technology company that focuses on providing game changing products, services and ideas, announced today that the Company's Thermomedics, Inc. division, makers of the world's leading TouchFreeTM Clinical Thermometer, Caregiver®, has signed a comprehensive distribution agreement with Alliant Healthcare Products, a leading distributor of healthcare products to federal supply channels.

http://www.globenewswire.com/news-release/2015/02/24/709180/10121579/en/Sanomedics-Signs-Comprehensive-Distribution-Agreement-With-Alliant-Healthcare-Products.html

January 27, 2015

Detecting Ebola with Infrared Light
A non-contact thermometer is changing the way the Centers for Disease Control (CDC) tackle Ebola.

The Caregiver thermometer was developed by Sanomedics with “TouchFree” – infrared – technology. Since it received FDA clearance and became available for purchase in 2012, it has gone around the world to airports that see traffic from countries with Ebola outbreaks, as well as to the United States embassy in Iraq and the consulate in Liberia. See more at: http://www.mdtmag.com/news/2015/01/detecting-ebola-infrared-light

January 26, 2015

How Many Ebola Patients Have Been Treated Outside of Africa?

At least 24 cases have been treated in Europe and the United States. Many were health and aid workers who contracted Ebola in West Africa and were transported back to their home countries for treatment. The latest patient in the United States to have the disease arrived on Nov. 15 and died three days later while being treated in a biocontainment center in Omaha. Cases shown below are compiled from reports by the C.D.C., the World Health Organization, Doctors Without Borders and other agencies. See more at: http://www.nytimes.com/interactive/2014/07/31/world/africa/ebola-virus-outbreak-qa.html?_r=0

UN says despite progress fight against Ebola is far from won

By EDITH M. LEDERER, The Associated Press

UNITED NATIONS — Close to 1,000 new cases of Ebola were recorded in the last three weeks despite progress in combatting the deadly disease and "the fight is far from won," the U.N. mIssion chief in West Africa said Tuesday. - See more at: http://news.yahoo.com/un-says-despite-progress-fight-against-ebola-far-232455314.html

October 31, 2014

Power tweets picture of airport Ebola screening

(CNN) -- As fear about the spread of Ebola continues, U.S. Ambassador to the United Nations Samantha Power says she'll be following standard health protocol following her return from Africa.
-See more at: http://www.cnn.com/2014/10/31/politics/power-ebola-tweet

October 17, 2014

EBOLA VIRUS 'ENTRY SCREENINGS' FOR SYMPTOMS AT O'HARE

Ebola virus screenings for symptoms like fever began Thursday at O'Hare Airport for travelers on flights from Liberia, Sierra Leone or Guinea. Customs and health officials at O'Hare are taking passengers' temperatures with digital no-touch thermometers. Passengers will also be asked whether they've been near anyone sick. -See more at: http://abc7chicago.com/travel/ebola-virus-entry-screenings-for-symptoms-at-ohare/352918

The CDC just rush-ordered 80 of these high-tech thermometers to screen for Ebola

The Centers for Disease Control is taking a page out of international Ebola workers' playbooks and is ordering dozens of thermometers that don't require touching the patient, according to the company supplying the devices. -See more at: http://www.washingtonpost.com/blogs/the-switch/wp/2014/10/15/the-cdc-just-rush-ordered-80-of-these-high-tech-thermometers-to-screen-for-ebola

How A No-Touch Thermometer Detects A Fever

In the battle to stop Ebola's spread, health officials worldwide have been deploying thermometers in hopes of detecting the earliest symptoms among people who might be sick. The no-contact thermometer, already broadly used in some airports in Africa, has come to U.S. airports this week — now at New York's John F. Kennedy Airport, and, starting Thursday, at D.C.'s Dulles, Chicago's O'Hare, Atlanta's Hartsfield-Jackson, and Newark's Liberty.
-See more at: http://krwg.org/post/how-no-touch-thermometer-detects-fever

October 16, 2014

Caregiver® no-touch thermometers have been enlisted in the fight against Ebola - 

MIAMI, - Sanomedics International Holdings, Inc. (OTCQB:SIMH), announced today that the Company's Caregiver® TouchFree™ InfraRed Thermometers help to reduce contagion risk for health workers in hospitals, clinics and other healthcare facilities across the country. The devices have also begun service at major U.S airports for Ebola screening of passengers traveling from high risk locations. The Company's Thermomedics, Inc. division is distributing the thermometers across the healthcare spectrum.

During a television interview Sunday on NY1 News, Keith Houlihan, Sanomedics' Founder and President, mentioned that authorities have been quick to recognize the technology's strong clinical documentation, accuracy and safety. He noted that "unlike industrial and consumer infrared thermometers, Caregiver® is FDA-cleared as a clinical thermometer for use by medical professionals. Our Thermometers are uniquely suited to this type of highly infectious virus, since the method of transfer is via contact with body fluids and contaminated substances from the victims."

Thermomedics' VP of Marketing and Sales, Ron Benincasa, indicated that the speed of the process, the simplicity of technique (one-button operation), and the protection of the temperature-takers make this an ideal tool in this urgent effort. Besides the efforts at airports, Caregiver is being used in hospitals and clinics around the world.

- See more at: http://www.healthcarefacilitiestoday.com/posts/Sanomedics-announces-that-their-Caregiver-notouch-thermometers-have-been-enlisted-in-the-fight-against-Ebola-Press-Releases--6990#sthash.bE9ziqMR.dpuf

October 13, 2014

No-Touch Thermometers Aim to Reduce Risk for Health Workers

For the first time, the world is getting a closer look at the no-touch thermometers that are being used to take the temperatures of passengers coming into JFK from West Africa. 
-See more at: http://www.ny1.com/content/lifestyles/health_and_medicine/217153/no-touch-thermometers-aim-to-reduce-risk-for-health-workers

September 18, 2014

Company News

Sanomedics (OTCQB: SIMH) Announces Initial Orders of Thermomedics' Caregiver® TouchFree™ Clinical Thermometers to Help Fight Ebola Outbreak in West Africa

Thermomedics has sent the first 20 units to the Firestone Natural Rubber Company, whose personnel are involved in this urgent healthcare battle.

July 16, 2014

Company News

Sanomedics International Holdings, Inc. Subsidiary Thermomedics' Caregiver® Thermometer with TouchFree™ Technology Inks 3-YR pact with Novation.

The revolutionary new device continues to gain traction in the Clinical Marketplace with new agreement to supply Novation, which operates 40 percent of the staffed beds in the United States!

 

About PositiveID Corporation

PositiveID Corporation is a life sciences tools and diagnostics company that develops biological detection systems for point-of-need testing and America's homeland defense industry. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID's future expectations, including the likelihood that the established distribution and customer channels, including the federal government, for Caregiver are expected to provide synergies to PositiveID as it continues the development and testing of its Firefly Dx real-time pathogen detection system and prepares for commercialization; the likelihood that the evolving business opportunities for Caregiver will contribute revenue to the Company in 2016; the likelihood that the additional qualitative synergies of an experienced management team with proven regulatory, sales, distribution and manufacturing expertise will be of great value when the Company reaches commercialization of Firefly Dx; the likelihood that the global market for temperature monitoring devices will reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola; the likelihood that the Stock Purchase Agreement will close in the first quarter of 2016; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the bio-threat detection and rapid medical testing sectors; the Company's ability to complete the development and commercialization of its Firefly Dx system; the Company's ability to complete the acquisition of Thermomedics; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 30, 2015, and 10-Qs filed on November 12, 2015, August 13, 2015, and May 15, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=946050